Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. filed this Form 8-K on May 23, 2023, reporting an underwritten public offering of its common stock. The offering was expected to close on May 26, 2023, subject to customary closing conditions.
Offering and Key Financial Metrics
| Item | Details |
|---|---|
| Shares offered | 11,125,000 shares of common stock |
| Public offering price | $11.75 per share |
| Underwriting purchase price | $11.045 per share |
| Expected net proceeds | Approximately $122.4 million, after underwriting discounts, commissions, and estimated offering expenses |
| Overallotment option | Underwriters may purchase up to 1,668,750 additional shares during a 30-day period |
| Expected net proceeds including full option exercise | Approximately $140.8 million |
The filing does not provide revenue, profit or loss, cash flow, operating margin, debt, cash balance, or post-offering liquidity metrics.
Material Changes Versus the Prior Comparable Period
This filing does not report period-over-period operating results. The material transaction is the planned issuance of additional common stock, which would increase the company’s share count and dilute existing stockholders. The filing does not provide the resulting pro forma share count or ownership percentages.
Guidance, Outlook, Risks, and Unusual Items
- Management expects the offering to generate approximately $122.4 million in net proceeds, or approximately $140.8 million if the underwriters exercise their option in full.
- Completion of the offering and proceeds are forward-looking matters subject to market conditions and customary closing conditions.
- The underwriting agreement includes customary representations, warranties, covenants, indemnification obligations, closing conditions, and termination provisions.
- The offering is being conducted under the company’s effective Form S-3 shelf registration statement.
- The filing does not specify the intended use of the offering proceeds.
- Risks include failure to satisfy closing conditions, adverse market conditions, and risks described in Phathom’s other SEC filings.
Investor Verification Points
- Verify whether the offering closed on the expected date and the final number of shares issued.
- Confirm whether the underwriters exercised any portion of the 1,668,750-share overallotment option.
- Reconcile actual net proceeds with the estimates disclosed in this filing.
- Review subsequent filings for the use of proceeds, updated cash runway, share dilution, debt, and operating results.
- Review the full underwriting agreement and the company’s other SEC filings for additional contractual and business risks.